7 terminated. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Terminated 7 |
| Phase 2 | 4 | Terminated 4 |
Follow TMZ: new trials by email Literature Review of TMZ trials Research Report on TMZ
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy (IMRT), Temozolomide - Glioblastoma, Gliosarcoma | Phase 1 | Terminated | Barbara Ann Karmanos Cancer Institute | 2 | 2021-08-12 | 2025-01-15 |
| A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer Talazoparib, Temozolomide - Prostate Cancer, Prostate Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 16 | 2019-07-11 | 2026-08-24 |
| T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery T-DM1, TMZ - Breast Cancer, Brain Metastasis | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 12 | 2018-04-18 | 2023-10-11 |
| BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma Nanoliposomal Irinotecan, Temozolomide - Glioblastoma Multiforme, Glioblastoma | Phase 1 / Phase 2 | Terminated | Brown University | 12 | 2017-11-30 | 2022-12-13 |
| Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs TAS-102, Temozolomide, Filgrastim - Neuroendocrine Tumors, Neoplasms | Phase 1 | Terminated | University of Wisconsin, Madison | 18 | 2017-08-22 | 2022-09-23 |
| Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma ascorbic acid, temozolomide, quality-of-life assessment - Anaplastic Astrocytoma, Anaplastic Oligodendroglioma | Phase 1 | Terminated | University of Nebraska | 4 | 2014-06-16 | 2023-11-24 |
| Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma PS-341 (VELCADE), temozolomide, immunoenzyme technique - Brain and Central Nervous System Tumors, Melanoma | Phase 1 / Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 47 | 2003-06-01 | 2012-10-02 |
Glioblastoma (3) · Brain Neoplasms (2) · Gliosarcoma (2) · Astrocytoma (1) · Breast Neoplasms (1) · Central Nervous System Neoplasms (1) · Melanoma (1) · Neoplasms (1) · Neuroectodermal Tumors, Primitive (1) · Neuroendocrine Tumors (1) · Oligodendroglioma (1) · Prostatic Neoplasms (1)
Barbara Ann Karmanos Cancer Institute (1) · Brown University (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · University of Nebraska (1) · University of Wisconsin, Madison (1) · Vanderbilt-Ingram Cancer Center (1)
United States (7)
Howard Safran, MD (1) · Jeffrey A. Sosman, MD (1) · Karen Autio, MD (1) · Michael Dominello, M.D. (1) · Nataliya Uboha, MD (1) · Nicole Shonka, MD (1) · Stanley Lipkowitz, M.D. (1)
PMID 32270710, PMID 33284237, PMID 36705597, PMID 40906325
P30CA036727 (1)